SAB Biotherapeutics (SABS) Capital Expenditures (2021 - 2026)

SAB Biotherapeutics has reported Capital Expenditures for 5 years, with the latest figure at $255376.0 in Q1 2026.

• For the quarter ending Q1 2026, Capital Expenditures changed N/A year-over-year to $255376.0; the trailing twelve-month figure through Mar 2026 stood at $463564.0 (changed N/A YoY), and the FY2025 full-year result was $933156.0, up 176.69% from the prior year.
• Capital Expenditures for Q1 2026 stood at $255376.0, up from $55377.0 in the prior quarter.
• The five-year high for Capital Expenditures was $1.4 million in Q1 2022, with the low at $21300.0 in Q1 2023.
• Historically, Capital Expenditures has averaged $227400.5 across 4 years, with a median of $85306.0 in 2023.
• Annual changes were most pronounced in 2023 — Capital Expenditures sank 98.43% — and 2024, when it jumped 505.98%.
• SAB Biotherapeutics' Capital Expenditures stood at $117754.0 in 2022, then tumbled by 42.37% to $67864.0 in 2023, then declined by 18.4% to $55377.0 in 2024, then surged by 361.16% to $255376.0 in 2026.
• The last three Capital Expenditures figures came in at $255376.0 (Q1 2026), $55377.0 (Q4 2024), and $100300.0 (Q3 2024), per Business Quant data.